Reported about 23 hours ago
The U.S. Department of Health and Human Services plans to lay off 20,000 employees, which could significantly affect the development of new drugs and therapies. Experts, including Dr. Ezekiel Emanuel, emphasize the critical role of government funding in biomedical research, arguing that the private sector cannot entirely replace the public sector's contributions. The potential cuts raise concerns about the sustainability of a vital ecosystem that relies on collaboration between government, universities, and drug companies.
Source: YAHOO